

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Fulvestrant for the treatment of locally advanced or metastatic breast cancer

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

Version of matrix of consultees and commentators reviewed:					
Provisional matrix of consultees and commentators sent for consultation					
Summary of comments, action taken, and justification of action:					
	<i>Proposal:</i>	<i>Proposal made by:</i>		<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>
				To be discussed at scope sign off meeting	
1.	Remove Confederation of Indian Organisations from patient/carer group consultees.	NICE Secretariat		Removed	Confederation of Indian Organisations have now closed, and therefore been removed from the matrix.

2.	Add Care Quality Commission (CQC) to general group commentators.	NICE Secretariat		Added	Care Quality Commission meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a general group commentator.
3.	Remove National Cancer Alliance from patient/carer group consultees	NICE Secretariat		Removed	National Cancer Alliance have now closed, and therefore been removed from the matrix.
4.	The matrix of consultees states that Pfizer is a manufacturer of tamoxifen. Pfizer is not a manufacturer of tamoxifen and this statement should be amended.	Pfizer		Noted	Statement amended as requested as per specific organisation's request.